Pfizer's talazoparib extends PFS in phase III trial in metastatic breast cancer

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

The NRG Oncology NSABP B-39/RTOG 0413 clinical trial compared whole-breast irradiation to accelerated partial-breast irradiation and determined that APBI was not statistically equivalent to WBI in local tumor control. The secondary outcome for the trial was quality-of-life.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Kisqali + aromatase inhibitor for early high-risk breast cancer

FDA approved Kisqali (ribociclib) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage 2 and 3 early breast cancer at high risk of recurrence.

September 20, 2024

Vol.50 No.35

Obituary

Richard A. Rettig, author of an acclaimed history of the National Cancer Act, dies at 87

Richard A. Rettig, the author of an authoritative history of the writing of the National Cancer Act of 1971, died on Aug. 7.

DNA methylation contributes to 9/11-related breast cancers

A study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has highlighted the role of DNA methylation in the increased risk of several cancers, including breast cancer, among rescuers and survivors of the attack on the World Trade Center on Sept. 11, 2001, in New York City.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Mechanisms that clear mutations drive field cancerization in mammary tissue

A defensive mechanism responsible for normal remodeling of breast tissue during the menstrual cycle is a potential driver of breast cancer development, according to research by the Cancer Grand Challenges research team PRECISION.

September 13, 2024

Vol.50 No.34

In Brief

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care.

September 06, 2024

Vol.50 No.33

Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer

YOU MAY BE INTERESTED IN

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

FDA approves Kisqali + aromatase inhibitor for early high-risk breast cancer

Richard A. Rettig, author of an acclaimed history of the National Cancer Act, dies at 87

DNA methylation contributes to 9/11-related breast cancers

Mechanisms that clear mutations drive field cancerization in mammary tissue

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login